Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives $6.75 Average Target Price from Analysts
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) have earned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price […]
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) have earned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price […]
